Prof Jacqueline (“Jackie”) Hunter (CBE FMedSci FBPharmacolS FRSB FZL PhD Hons DSc) has had over 30 years of experience in the pharmaceutical and biotechnology industry. She led neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline, bringing a number of drug molecules to proof of concept in patients. In 2010, after leaving GSK, she established her own company, OIPharmaPartners, to drive open innovation in the life sciences. From 2013-2016 she was Chief Executive of the Biotechnology and Biological Sciences Research Council and then moved to BenevolentAI, a company using AI to drive innovation in pharmaceutical R&D. She remains a Board director of BenevolentAI, is Chair of the Stevenage Bioscience Catalyst and Chair of the Trustees of The Sainsbury Laboratories in Norwich. She is also a visiting professor at St Georges Hospital Medical School and Imperial College, London.
Dr Michalis Papadakis is the CEO and co-founder of Brainomix. He leads the management team, commercial strategy, fund raising, and corporate partnerships. He has grown the company from the ground up, building the company’s global presence and has raised over £15 million of private investment and public funding. When he founded Brainomix he was the Scientific Director of the preclinical stroke lab at the University of Oxford. He has a BSc Honours in Biochemistry from Imperial College London and a PhD in neurosciences from UCL School of Pharmacy. He has been an invited speaker at international scientific and innovation conferences.
Professor Dr. Dr.-Ing.h.c. Heinz-Otto Peitgen ("HO") brings immense medical imaging and AI technology expertise together with commercial experience bringing medical imaging software to market. He was a Professor of Mathematics and Biomedical Sciences at the University of Bremen and Florida Atlantic University. He founded and directed the research center Fraunhofer MEVIS, Institute for Digital Medicine, and founded the company MeVis Medical Imaging AG, which has been on the German stock market since 2007. During his long-standing career he pioneered medical imaging in oncology, as well as neurodegenerative and cardio-vascular diseases.
Frank is the Global Head of the Boehringer Ingelheim Venture Fund. He served as board member of STAT Diagnostica (acquired by Qiagen in 2018), Hookipa Biotech (IPO at NASDAQ in 2019) and Amal Therapeutics (acquired by Boehringer Ingelheim in 2019). Currently, he is on the Boards of Cardior Pharmaceuticals, eTheRNA, Aelin Therapeutics, RinRi Therapeutics, Acousia Therapeutics, and Brainomix.
Frank is a physician by training did his PhD in Pharmacology and specialized in Pharmacology and Toxicology. He spent more than 10 years in academic research in the Max-Planck-Institute for Molecular Genetics in Berlin and in the Institute of Pharmacology of the Freie Universität, Berlin.
He began his industrial career at Schering AG and moved in 1999 to Boehringer Ingelheim joining Pulmonary Research. In 2005, he took over the responsibility for the Licensing Department. In this function, he was responsible for the licensing activities of the German Boehringer Ingelheim organization in various indication areas. In addition, he built up the Biological Research unit at the German Research site in Biberach.
In 2010 - shortly after its initiation - Frank joined the Boehringer Ingelheim Venture Fund.
Mark Jaffray joined the Brainomix Board as an Investor Director in 2014, with a background as a prolific investor in high-growth innovative companies. He earned an LLB (Hons) / BCA in Law and Accounting from Victoria University of Wellington, and certificates from Harvard Business School, London Business School and the Haas Business School at the University of California, Berkeley.
David Ball represents Parkwalk Advisors on the Brainomix board. David has 20 years’ experience in financial markets, including 15 years as equity portfolio manager and partner with Tudor Investment Corp. David is a Chartered Accountant, and holds undergraduate and postgraduate degrees in Engineering from Cambridge University.
Andrew is Brainomix Chairman. Andrew has an MBA from the Wharton School of the University of Pennsylvania, and a BSc in Computer Systems Engineering from the University of Kent at Canterbury. He is an experienced NED and investor in early stage companies. He was involved in the early stages of Internet computing over in Silicon Valley and later worked to build Intel’s UK venture arm.